Compare Novavax Inc (NVAX) vs Tenet Healthcare Corporation (THC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novavax Inc vs Tenet Healthcare Corporation — how do they compare? Novavax Inc trades at $11.09 (market cap $1.82B), while Tenet Healthcare Corporation trades at $262.03 (market cap $20.98B). The key difference: Tenet Healthcare Corporation is far larger — about 11.5× Novavax Inc's market cap, and Tenet Healthcare Corporation is more actively traded (428,008 versus 6,198,505). Which is the better fit depends on your goals — on Pluang, investors hold Novavax Inc for 59 Days and Tenet Healthcare Corporation for 15 Days on average.
| NVAX | THC | |
|---|---|---|
Market Cap | $1.82B | $20.98B |
Volume | 6,198,505 | 428,008 |
Sector | Health | Health |
52-Week High | $12.56 | $280.77 |
52-Week Low | $6.22 | $161.37 |
Typical Hold Time | 59 Days | 15 Days |
Enterprise Value | $1.39B | $32.06B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Novavax (NVAX) trades at $11.22, down 0.88% on the day, with a bullish technical signal from moving averages and a neutral RSI. The company reported strong revenue of $1.12 billion in 2025 and a net income of $440.30 million, but faces negative cash flow and a projected net loss for 2026. Recent news highlights its strategic pivot to a partnership-driven model using its Matrix-M adjuvant technology, with regulatory approvals for its updated COVID-19 vaccine in key markets.
The outlook for NVAX is mixed, with analyst consensus strongly favoring a buy rating (73.92%) but significant financial risks including negative equity, persistent cash burn, and volatile earnings. Investment opportunity lies in the successful execution of its licensing strategy and expansion into oncology, though execution risks and competitive pressures remain key concerns for shareholders.
Tenet Healthcare (THC) trades at $259.83, up 0.53% with a bullish technical signal. The stock shows strong fundamentals with consistent earnings beats (Q4 2025-Q2 2026) and robust profitability (ROE 53.31%, net margin 9.9%). Recent news highlights strong cash flow supporting capital returns and upcoming Q3 2026 results on October 29. Valuation appears reasonable with P/E of 10.07 and EV/EBITDA of 5.75.
THC presents a compelling investment case with strong analyst support (81% buy ratings) and 7% upside to consensus target of $283.36. Key catalysts include sustained earnings momentum and efficient capital allocation. Risks include surgical volume pressures and cash flow sustainability concerns amid aggressive buybacks. The stock's current technical setup near pivot point $259 suggests balanced risk-reward.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Novavax Inc
Novavax, Inc. is a clinical stage biotechnology company. The Company creates novel vaccines to address a broad range of infectious diseases worldwide using proprietary virus-like particle (VLP) technology.
Read more on NVAX →About Tenet Healthcare Corporation
Tenet Healthcare is a leading diversified healthcare services company that has strategically pivoted toward high-growth ambulatory care. Operating through United Surgical Partners International (USPI), the largest ambulatory platform in the U.S., Tenet manages an expansive network of surgical centers, acute care hospitals, and specialty facilities. The company’s focus on high-acuity services and operational efficiency, supported by its revenue cycle management subsidiary Conifer Health Solutions, positions it as a resilient leader in the evolving U.S. healthcare landscape.
Read more on THC →
